David A. Siegel Verona Pharma PLC Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Verona Pharma PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,000 shares of VRNA stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,000Holding current value
$1.22 Million% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding VRNA
# of Institutions
216Shares Held
70.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$411 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$359 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$217 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$201 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$201 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.92B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...